STIFEL 2026 HEALTHCARE CONFERENCE - EUPRAXIA PHARMACEUTICALS INC

Based on the transcript provided, here is the summary of forward-looking statements from Eupraxia (referred to as Eupaxia/Eupoxia in the text):

• Explicit Guidance:

  • No financial guidance provided: The transcript contains no specific revenue, earnings, cash flow, or capital expenditure guidance. The company is a clinical-stage biotechnology firm focused on product development, not commercial revenue generation.
  • Data Release Timing: Interim Phase IIb data for Eosinophilic Esophagitis (EOE) is expected "soon" (implied near-term relative to the call), covering 6-month primary endpoints and 52-week durability data.
  • Trial Outcomes Expectation: Management expects statistical significance to be achievable upon full recruitment (40 patients per arm), projecting strong separation from placebo if interim data trends hold. They anticipate a "delta from placebo" of 4 to 10 points on symptom scales (DSQ/SDI) to be commercially viable.

• Business-Segment Outlook:

  • Primary Indication (EOE): The Phase IIb trial in Eosinophilic Esophagitis is on track for an interim readout. Management targets a mid-2027 launch for the Phase III trial initiation in this segment.
  • Secondary Indications (Pipeline Expansion):
    • Benign Esophageal Strictures: Anticipated to enter Phase II (potentially adaptive design transitioning to Phase III) "around" 2027, leveraging KOL feedback and the drug's ability to reverse fibrosis.
    • Fibrostenotic Crohn's Disease & Ulcerative Colitis: Targeted for development "further down the line" (post-2027).
    • Technology Platform: The "Diffusphere" platform aims to deliver zero-order kinetics for 52 weeks (with potential for longer duration), targeting local tissue delivery to minimize systemic side effects.

• Market and Competitive Outlook:

  • Epidemiology Growth: The diagnosed patient population in the U.S. is expanding rapidly, moving from 150,000 (2022) to 500,000–600,000 (present), driven by increased diagnosis and potentially environmental factors (e.g., "Tide Pods" mention) suggesting underlying prevalence growth.
  • Competitive Advantage: The product targets a one-year dosing interval, positioning it as transformational compared to daily oral steroids, weekly/bi-weekly biologics, and six-month dosing schedules. This aligns with the existing 60% of patients who undergo annual endoscopies but currently receive no therapy during the procedure.
  • Practice Economics: The model is designed for a "buy-and-bill" medical benefit structure, allowing Gastroenterologists to bill a therapeutic CPT code (Modifier 59) and ASP plus six, incentivizing adoption similar to the launch of Intuity (Intravita).

• Macro / Industry Outlook:

  • Regulatory Path: The company is navigating the "noise" in Patient-Reported Outcomes (PROs) like the DSQ scale; they have designed the trial to be robust against this variability, utilizing histologic endpoints (EOEHS) which do not show placebo movement.
  • Safety Standards: Management targets a candidiasis rate of <2%, contrasting with industry rates of 5–50% for oral steroids, to differentiate the product on the safety profile.
  • Payer Alignment: The strategy explicitly targets reducing emergency room visits and food impactions, framing the therapy as cost-effective for payers by preventing expensive acute care events.

• Strategic Initiatives:

  • Clinical Trial Acceleration: The EOE Phase IIb trial recruited at twice the rate of any other trial in the space, indicating strong physician and patient demand and operational efficiency.
  • Protocol Design: The trial utilized an adaptive design with built-in "wiggle room" for statistical power; a pre-specified analysis confirmed the current sample size (20 patients/arm at interim) is sufficient to reach significance at the full recruitment level (40 patients/arm) without needing expansion.
  • Commercial Readiness: Development is structured to align with the annual endoscopy guideline (60% compliance target), intending to induce compliance by tying therapy to a procedure patients are already undergoing.
  • Safety Data: 3,000 injections have been performed to date with zero complications reported, de-risking the procedural safety profile for future regulatory filings.

• Risks and Headwinds to Outlook:

  • Statistical Power Variability: While the interim data is not powered for significance, there is a risk that full recruitment (40 patients/arm) may not achieve the required statistical separation on symptom scales (DSQ/SDI) due to the inherent "noise" in PRO data.
  • Placebo Effect & Variability: High variability in the patient population and the placebo effect on symptom reporting could obscure treatment differences, although histologic endpoints are expected to be more robust.
  • Adoption Barriers: Potential resistance from allergists who may be hesitant to refer patients to Gastroenterologists for annual monitoring, though management expects this to be mitigated by the "buy-and-bill" economic incentive.
  • Timeline Dependencies: The 2027 target for EOE Phase III initiation is contingent on the successful interim data readout; any negative outcome in the interim could stall or alter the protocol.

• Management Tone on the Future:

  • High Confidence: Management expresses a "very high degree of confidence" regarding the translation of histologic data to clinical success and the durability of the 52-week effect.
  • Transformational Viewpoint: There is a strong conviction that the one-year dosing interval represents a "transformational" shift in the market, addressing a critical compliance gap left by daily or weekly alternatives.
  • Collaborative Stance: Tone is cooperative with KOLs and physicians, emphasizing that the technology solves immediate workflow inefficiencies (e.g., "five-minute addition" to an existing scope) rather than requiring new behaviors.

• Miscellaneous:

  • Technology Distinction: The product utilizes "zero-order kinetics" to maintain therapeutic levels for ~52 weeks, distinguishing it from immediate-release steroids.
  • Patient Experience: Anecdotal evidence suggests patients are "mind-set changed," reporting a return to normal life (eating steak, socializing) without active treatment, which management believes will drive strong patient retention and advocacy.